{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.01","upperLimit":"9.63","value":"7.66"},{"groupId":"OG001","lowerLimit":"6.18","upperLimit":"11.07","value":"8.08"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"211"},{"groupId":"OG001","value":"206"}],"units":"Participants"}],"description":"Time to first worsening of the brief pain inventory short form modified (mBPI-sf) \"worst pain score\" was defined as the time from the date of the first study drug dose (baseline date) to the first date of a \"worst pain\" score increase of greater than or equal to (≥) 2 points from baseline. The mBPI-sf is an 11-item instrument used as a multiple-item measure of cancer pain intensity ranging from 0 (no pain or does not interfere) and ranged through 10 (pain as bad as you can imagine or completely interferes).","dispersionType":"95% Confidence Interval","groups":[{"description":"75 milligrams per meter squared (mg/m\\^2) doxorubicin administered intravenously (IV) on day 1 of each 21 day cycle for 8 cycles plus 20 milligrams per kilogram (mg/kg) dose of olaratumab administered IV on day 1 and day 8 of cycle 1 and 15 mg/kg olaratumab administered IV on day 1 and day 8 of cycles 2-8. Beginning with cycle 9, 15 mg/kg olaratumab administered IV on day 1 and day 8 of each subsequent 21 day cycle until documented progressive disease (PD) or discontinuation for any other reason.","id":"OG000","title":"Doxorubicin + Olaratumab"},{"description":"75 mg/m\\^2 doxorubicin administered IV on day 1 of each 21 day cycle for 8 cycles plus placebo (equivalent volume) administered IV on day 1 and day 8 for 8 cycles. Beginning with cycle 9, placebo (equivalent volume) administered on days 1 and 8 of each subsequent 21 day cycle until PD or discontinuation for any other reason.","id":"OG001","title":"Doxorubicin + Placebo"}],"paramType":"MEDIAN","populationDescription":"All randomized participants who completed at least 1 baseline assessment and at least 1 subsequent assessment during the study period.","reportingStatus":"POSTED","timeFrame":"Randomization through Follow-up (Up to 34.5 Months)","title":"Time to First Worsening of the Brief Pain Inventory Short Form Modified (mBPI-sf) \"Worst Pain Score\"","type":"SECONDARY","unitOfMeasure":"Months"}